Sepracor Surges Amid Dainippon Takeover Talk
This article was originally published in The Pink Sheet Daily
Executive Summary
If the $2.7 billion deal materializes, Japanese pharma would gain sales force for lurasidone plus promising CNS candidates.
You may also be interested in...
Dainippon Sumitomo Awakes To U.S. Market - Buys Sepracor For $2.6 Billion
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization
Dainippon Sumitomo Awakes To U.S. Market - Buys Sepracor For $2.6 Billion
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization
Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.